Asia’s super-aging societies are sparking a boom in high-end longevity clinics—even if ‘public enthusiasm’ is outpacing the science

A new kind of business—blending hospitality, technology, and traditional practices—is promising to extend not just lifespan, ...

AstraZeneca to pay $200M upfront for Sino Biopharmaceutical’s COPD drug license deal

AstraZeneca (AZN) has secured global rights (excluding China) to an experimental chronic obstructive pulmonary disease (COPD) treatment, TQC3721, from a subsidiary of Hong Kong-listed Sino ...